Sjögren Disease—B Cells at the Brink: From Autoimmunity to Lymphomagenesis and the Rise of Novel B Cell–Targeted Therapies - Scorecard - MDSpire

Sjögren's Syndrome: The Role of B Cells in Autoimmunity, Lymphoma Development, and Emerging B Cell-Directed Treatments

  • By

  • Rachael A. Gordon

  • Sara S. McCoy

  • July 1, 2026

Share

Clinical Scorecard: Sjögren's Syndrome: The Role of B Cells in Autoimmunity, Lymphoma Development, and Emerging B Cell-Directed Treatments

At a Glance

CategoryDetail
ConditionSjögren's Syndrome
Key MechanismsB cells contribute to pathogenesis by producing autoantibodies, presenting self-antigens, and releasing cytokines.
Target PopulationPatients with Sjögren's Syndrome, including those with extraglandular manifestations.
Care SettingClinical research and management of autoimmune diseases.

Key Highlights

  • Sjögren's Syndrome is highly heterogeneous with diverse symptoms and organ involvement.
  • Endotyping may improve understanding and treatment of Sjögren's Syndrome.
  • B cells are critical in the pathogenesis of Sjögren's Syndrome.
  • Lymphoma risk is associated with specific endotypes of Sjögren's Syndrome.
  • Research is ongoing to validate endotypes and their therapeutic implications.

Guideline-Based Recommendations

Diagnosis

  • Utilize clinical criteria and laboratory tests, including serology for autoantibodies.

Management

  • Consider hydroxychloroquine for inflammatory symptoms.

Monitoring & Follow-up

  • Regular follow-up to assess disease activity and symptom burden.

Risks

  • Monitor for potential development of lymphoma in specific endotypes.

Patient & Prescribing Data

Individuals diagnosed with Sjögren's Syndrome, particularly those with inflammatory arthralgias.

Hydroxychloroquine is recommended for managing inflammatory symptoms.

Clinical Best Practices

  • Characterize patients using endotypes to tailor management strategies.
  • Monitor for extraglandular manifestations and adjust treatment accordingly.
  • Engage in shared decision-making with patients regarding their treatment plans.

Related Resources & Content

Original Source(s)

Sjögren Disease—B Cells at the Brink: From Autoimmunity to Lymphomagenesis and the Rise of Novel B Cell–Targeted Therapies

  • by Rachael A. Gordon, Sara S. McCoy

  • July 1, 2026

Related Content

Targeting the synovial engine: next-generation engineered immune cells to eradicate pathogenic FLS in rheumatoid arthritis, with safety-first, selective designs

Joint Site May Influence RA Treatment Response

A Swiss registry study found that the wrist and second and third metacarpophalangeal joints consistently resolved more slowly than most other joints following biologic or targeted synthetic therapy.

RA Genetics May Reveal Link to Gum Disease

Analysis of East Asian genetic data found a modest inverse association between rheumatoid arthritis susceptibility and periodontitis risk, though researchers said the findings require confirmation in independent cohorts.